Ku JH - Search Results

1

Weekly versus 2-weekly versus 3-weekly docetaxel to treat metastatic castration-resistant prostate cancer.

Yuk HD, Kim M, Keam B, Ku JH, Kwak C, Jeong CW. Yuk HD, et al. Among authors: ku jh. Prostate Int. 2024 Dec;12(4):219-223. doi: 10.1016/j.prnil.2024.09.002. Epub 2024 Sep 26. Prostate Int. 2024. PMID: 39735199 Free PMC article.

2

PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.

Kang M, Lee KH, Lee HS, Park YH, Jeong CW, Ku JH, Kim HH, Kwak C. Kang M, et al. Among authors: ku jh. Prostate. 2016 Feb 15;76(3):273-85. doi: 10.1002/pros.23118. Epub 2015 Oct 26. Prostate. 2016. PMID: 26499308

3

Korean version of the convalescence and recovery evaluation: translation and linguistic validation.

Yuk HD, Kim JJ, Ku JH, Kwak C, Kim HH, Jeong CW. Yuk HD, et al. Among authors: ku jh. Prostate Int. 2020 Dec;8(4):158-166. doi: 10.1016/j.prnil.2020.05.001. Epub 2020 May 27. Prostate Int. 2020. PMID: 33425793 Free PMC article.

4

Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials.

Kang M, Jeong CW, Kwak C, Ku JH, Kim HH. Kang M, et al. Among authors: ku jh. Oncotarget. 2017 May 10;8(35):59690-59697. doi: 10.18632/oncotarget.17741. eCollection 2017 Aug 29. Oncotarget. 2017. PMID: 28938672 Free PMC article.

5

Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.

Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC, Ku JH. Kwak C, et al. Among authors: ku jh. J Surg Oncol. 2007 Mar 15;95(4):317-23. doi: 10.1002/jso.20669. J Surg Oncol. 2007. PMID: 17066434

6

Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.

Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Ku JH. Kwak C, et al. Among authors: ku jh. Tumori. 2007 Jan-Feb;93(1):68-74. doi: 10.1177/030089160709300112. Tumori. 2007. PMID: 17455874

7

No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?

Kwak C, Park YH, Jeong CW, Lee SE, Ku JH. Kwak C, et al. Among authors: ku jh. Urol Oncol. 2007 Jul-Aug;25(4):310-6. doi: 10.1016/j.urolonc.2006.08.022. Urol Oncol. 2007. PMID: 17628297

8

Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment.

Kwak C, Park YH, Jeong CW, Lee SE, Ku JH. Kwak C, et al. Among authors: ku jh. Urol Int. 2007;79(2):145-51. doi: 10.1159/000106329. Urol Int. 2007. PMID: 17851285

9

Chronic pulmonary disease negatively influences the prognosis of patients with advanced prostate cancer.

Jeong CW, Ku JH, Kwak C, Kim HH, Lee SE. Jeong CW, et al. Among authors: ku jh. World J Urol. 2009 Oct;27(5):643-52. doi: 10.1007/s00345-009-0375-3. Epub 2009 Feb 13. World J Urol. 2009. PMID: 19214529

10

Metachronous metastatic potential of small renal cell carcinoma: dependence on tumor size.

Ku JH, Moon KC, Kwak C, Kim HH. Ku JH, et al. Urology. 2009 Dec;74(6):1271-5. doi: 10.1016/j.urology.2009.04.072. Epub 2009 Jul 17. Urology. 2009. PMID: 19616288

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

517 results

Search Page

Filters